Investigational Drug Details
| Drug ID: | D216 |
| Drug Name: | Maraviroc |
| Synonyms: | -- |
| Type: | Chemical drug |
| DrugBank ID: | DB04835 |
| DrugBank Description: | Maraviroc (brand-named Selzentry, or Celsentri outside the U.S.) is a chemokine receptor antagonist drug developed by the drug company Pfizer that is designed to act against HIV by interfering with the interaction between HIV and CCR5. It was originally labelled as UK-427857 during development but was assigned the Maraviroc name as it entered trials. It was approved for use by the FDA in August, 2007. |
| PubChem ID: | 3002977 |
| CasNo: | 376348-65-1 |
| Repositioning for NAFLD: | Yes |
| SMILES: | C(C[C@H](NC(=O)C1CCC(CC1)(F)F)c1ccccc1)N1[C@@H]2C[C@@H](C[C@H]1CC2)n1c(C(C)C)nnc1C |
| Structure: |
|
| InChiKey: | GSNHKUDZZFZSJB-QYOOZWMWSA-N |
| Molecular Weight: | 513.677 |
| DrugBank Targets: | C-C chemokine receptor type 5 antagonist |
| DrugBank MoA: | Maraviroc is an entry inhibitor and works by blocking HIV from entering human cells. Specifically maraviroc is a selective, slowly reversible, small molecule antagonist of the interaction between human CCR5 and HIV-1 gp120. Maraviroc selectively binds to the human chemokine receptor CCR5 present on the membrane of CD4 cells (T-cells), preventing the interaction of HIV-1 gp120 and CCR5 necessary for CCR5-tropic HIV-1 to enter cells. |
| DrugBank Pharmacology: | Maraviroc is a chemokine receptor antagonist drug developed by the drug company Pfizer that is designed to act against HIV by interfering with the interaction between HIV and CCR5. |
| DrugBank Indication: | For treatment-experienced adult patients infected with only CCR5-tropic HIV-1 detectable, who have evidence of viral replication and HIV-1 strains resistant to multiple antiretroviral agents. |
| Targets: | CCR5 antagonist; CCR5 binder |
| Therapeutic Category: | Anti-fibrosis |
| Clinical Trial Progress: | Phase 2&3 completed (NCT03129113) |
| Latest Progress: | Under clinical trials |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L0498 | EUCTR2017-003172-32-GB | Phase 2 | Not Recruiting | No Results Available | 16/05/2018 | 9 November 2020 | Details |
| L0509 | ISRCTN31461655 | Phase 4 | Recruiting | No Results Available | 23/02/2018 | 21 February 2022 | Details |
| L0511 | EUCTR2017-003172-32-DE | Phase 2 | Not Recruiting | No Results Available | 06/02/2018 | 5 April 2021 | Details |
| L1000 | NCT03129113 | Phase 2/Phase 3 | Completed | No Results Available | March 1, 2017 | November 4, 2021 | Details |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs | |
|---|---|---|---|---|---|
| S03 | Anti-fibrosis | fibrosis | Angiotensin Receptor Blocker (ARB); CCR2/CCR5 antagonist; Thyroid receptor β agonist; PEGylated human FGF21 analogue; Monoclonal antibody to lysyl oxidase-like 2 (LOXL2); Galectin-3 inhibitor; FGF19 variant | Losartan; Cenicriviroc; VK-2809; MGL-3196; Pegbelfermin; Simtuzumab; GR-MD-02; NGM282 | Details |
| Article ID | PMID | Source | Title | |
|---|---|---|---|---|
| A07062 | 32636281 | BMJ Open | Protocol for a phase IV, open-label feasibility study investigating non-invasive markers of hepatic fibrosis in people living with HIV-1 and non-alcoholic fatty liver disease randomised to receiving optimised background therapy (OBT) plus maraviroc or OBT alone. | Details |
| A14409 | 29421523 | Transl Res | Maraviroc improves hepatic triglyceride content but not inflammation in a murine nonalcoholic fatty liver disease model induced by a chronic exposure to high-fat diet. | Details |
| A20028 | 26200028 | Rev Esp Quimioter | Maraviroc modifies gut microbiota composition in a mouse model of obesity: a plausible therapeutic option to prevent metabolic disorders in HIV-infected patients. | Details |
| A22338 | 24651825 | J Antimicrob Chemother | Maraviroc, a CCR5 antagonist, ameliorates the development of hepatic steatosis in a mouse model of non-alcoholic fatty liver disease (NAFLD). | Details |
| A47734 | 32739404 | Antiviral Res | The chemokine receptor antagonist cenicriviroc inhibits the replication of SARS-CoV-2 in vitro. | Details |